Recent development on COX-2 inhibitors as promising anti-inflammatory agents: The past 10 years

Zhiran Ju; Menglan Li; Junde Xu; Daniel C. Howell; Zhiyun Li; Fen-Er Chen

Acta Pharmaceutica Sinica B (Jun 2022)

Recent development on COX-2 inhibitors as promising anti-inflammatory agents: The past 10 years

Zhiran Ju,
Menglan Li,
Junde Xu,
Daniel C. Howell,
Zhiyun Li,
Fen-Er Chen

Affiliations

Zhiran Ju: Institute of Pharmaceutical Science and Technology, Zhejiang University of Technology, Hangzhou 310014, China; Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou 310014, China
Menglan Li: Institute of Pharmaceutical Science and Technology, Zhejiang University of Technology, Hangzhou 310014, China
Junde Xu: Institute of Pharmaceutical Science and Technology, Zhejiang University of Technology, Hangzhou 310014, China
Daniel C. Howell: Institute of Pharmaceutical Science and Technology, Zhejiang University of Technology, Hangzhou 310014, China
Zhiyun Li: Institute of Pharmaceutical Science and Technology, Zhejiang University of Technology, Hangzhou 310014, China
Fen-Er Chen: Institute of Pharmaceutical Science and Technology, Zhejiang University of Technology, Hangzhou 310014, China; Engineering Center of Catalysis and Synthesis for Chiral Molecules, Fudan University, Shanghai 200433, China; Shanghai Engineering Center of Industrial Asymmetric Catalysis for Chiral Drugs, Shanghai 200433, China; Corresponding author. Tel./fax: +86 571 88320242.

Journal volume & issue: Vol. 12, no. 6
pp. 2790 – 2807

Abstract

Read online

Cyclooxygenases play a vital role in inflammation and are responsible for the production of prostaglandins. Two cyclooxygenases are described, the constitutive cyclooxygenase-1 and the inducible cyclooxygenase-2, for which the target inhibitors are the non-steroidal anti-inflammatory drugs (NSAIDs). Prostaglandins are a class of lipid compounds that mediate acute and chronic inflammation. NSAIDs are the most frequent choices for treatment of inflammation. Nevertheless, currently used anti-inflammatory drugs have become associated with a variety of adverse effects which lead to diminished output even market withdrawal. Recently, more studies have been carried out on searching novel selective COX-2 inhibitors with safety profiles. In this review, we highlight the various structural classes of organic and natural scaffolds with efficient COX-2 inhibitory activity reported during 2011–2021. It will be valuable for pharmaceutical scientists to read up on the current chemicals to pave the way for subsequent research.

Published in Acta Pharmaceutica Sinica B

ISSN: 2211-3835 (Print); 2211-3843 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: http://www.journals.elsevier.com/acta-pharmaceutica-sinica-b

About the journal

Abstract

Keywords